| Literature DB >> 33535640 |
Alessia Giarraputo1, Ilaria Barison1, Marny Fedrigo1, Jacopo Burrello2, Chiara Castellani1, Francesco Tona3, Tomaso Bottio3, Gino Gerosa3, Lucio Barile2,4,5, Annalisa Angelini1.
Abstract
Cardiac allograft rejection following heart transplantation is challenging to diagnose. Tissue biopsies are the gold standard in monitoring the different types of rejection. The last decade has seen an increased emphasis on identifying non-invasive methods to improve rejection diagnosis and overcome tissue biopsy invasiveness. Liquid biopsy, as an efficient non-invasive diagnostic and prognostic oncological monitoring tool, seems to be applicable in heart transplant follow-ups. Moreover, molecular techniques applied on blood can be translated to tissue samples to provide novel perspectives on tissue and reveal new diagnostic and prognostic biomarkers. This review aims to provide a comprehensive overview of the state-of-the-art of the new methodologies in cardiac allograft rejection monitoring and investigate the future perspectives on invasive and non-invasive rejection biomarkers identification. We reviewed literature from the most used scientific databases, such as PubMed, Google Scholar, and Scopus. We extracted 192 papers and, after a selection and exclusion process, we included in the review 81 papers. The described limitations notwithstanding, this review show how molecular biology techniques and omics science could be deployed complementarily to the histopathological rejection diagnosis on tissue biopsies, thus representing an integrated approach for heart transplant patients monitoring.Entities:
Keywords: EMBs; Gene expression profiling; biomarkers; cardiac rejection monitoring; exosomes; heart transplant; liquid biopsy; mRNA; microRNA; tissue biopsy
Year: 2021 PMID: 33535640 PMCID: PMC7912846 DOI: 10.3390/biom11020201
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X